Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Nature Medicine

Volumn 25, Issue 1, 2019, Pages 89-94

  Scheper, Wouter ^a   Kelderman, Sander ^a   Fanchi, Lorenzo F ^a   Linnemann, Carsten ^a   Bendle, Gavin ^a   de Rooij, Marije A J ^a   Hirt, Christian ^b   Mezzadra, Riccardo ^a   Slagter, Maarten ^a   Dijkstra, Krijn ^a   Kluin, Roelof J C ^a   Snaebjornsson, Petur ^a   Milne, Katy ^c   Nelson, Brad H ^c   Zijlmans, Henry ^a   Kenter, Gemma ^a   Voest, Emile E ^a   Haanen, John B A G ^a   Schumacher, Ton N ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF BASEL   (Switzerland)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR;

CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL SELECTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LETTER; MALIGNANT NEOPLASM; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WHOLE EXOME SEQUENCING; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE; REPRODUCIBILITY; TUMOR ASSOCIATED LEUKOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; HUMANS; JURKAT CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; REPRODUCIBILITY OF RESULTS;

EID: 85058049841     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0266-5     Document Type: Article

References (34)

1. Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018)
2. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)
3. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003)
4. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015)
5. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)
6. Le, D. T. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015)
7. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015)
8. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012)
9. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017)
10. Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650 (2012)
11. Bobisse, S. et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 9, 1092 (2018)
12. +T cell response. Sci. Transl. Med. 6, 254ra128 (2014)
13. Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1, 409–418 (2012)
14. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015)
15. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439–e442 (2013)
16. Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018)
17. Pasetto, A. et al. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4, 734–743 (2016)
18. Gros, A. et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014)
19. Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016)
20. Dahlin, A. M. et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod. Pathol. 24, 671–682 (2011)
21. + tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538–18543 (2005)
22. Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014)
23. Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012)
24. Verdegaal, E. M. et al. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature 536, 91–95 (2016)
25. McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017)
26. Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141, 293–302 (2016)
27. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011)
28. Tang, F. et al. RNA-Seq analysis to capture the transcriptome landscape of a single cell. Nat. Protoc. 5, 516–535 (2010)
29. Bolotin, D. A. et al. MiTCR: software for T-cell receptor sequencing data analysis. Nat. Methods 10, 813–814 (2013)
30. Linnemann, C. et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat. Med. 19, 1534–1541 (2013)
31. Ochi, T. et al. Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy. Cancer Immunol. Res. 3, 1070–1081 (2015)
32. Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010)
33. + T cells in human melanoma. Nat. Med. 21, 81–85 (2015)
34. Gelman, A. et al. Bayesian Data Analysis. (CRC Press, Boca Raton, 2014)